|
JP2020164513A
|
|
In-blood free form aim increasing composition
|
|
WO2020071318A1
|
|
Therapeutic agent for neurodegenerative disease
|
|
JP2020158437A
|
|
Composition for increasing aim of free form in blood
|
|
CN111315880A
|
|
Mutant AIM
|
|
US2018224437A1
|
|
Method for examining renal disease
|
|
EP3103466A1
|
|
Preventive or therapeutic agent for kidney disease
|
|
CN104470531A
|
|
Prophylactic or therapeutic agent for hepatic diseases
|
|
WO2011145725A1
|
|
Method and kit for diagnosing aim-related illness
|
|
EP2572730A1
|
|
Method for prevention or treatment of metabolic syndrome
|
|
WO2011145722A1
|
|
Method of screening for compounds that control aim function
|
|
JPS6173057A
|
|
Discriminating instrument of pearl
|
